Trial Profile
A Double-Blind, Randomized, Placebo- and NRT -Controlled Phase II Study to Assess the Effects of EVT 302 Alone and in Combination With NRT on Craving and Withdrawal in Healthy Male Smokers Deprived of Cigarettes
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 25 Jun 2014
Price :
$35
*
At a glance
- Drugs Sembragiline (Primary) ; Nicotine
- Indications Smoking withdrawal
- Focus Therapeutic Use
- Sponsors Evotec NeuroSciences
- 25 Jun 2014 New trial record